Bevacizumab in Multiple Phase I Combinations

PHASE1CompletedINTERVENTIONAL
Enrollment

343

Participants

Timeline

Start Date

October 10, 2007

Primary Completion Date

April 29, 2020

Study Completion Date

April 29, 2020

Conditions
Advanced Cancer
Interventions
DRUG

Bevacizumab

2.5 mg/kg By Vein Over 90 Minutes.

DRUG

Sorafenib

200 mg By Mouth Daily for 28 Days

DRUG

Erlotinib

50 mg By Mouth Daily for 28 Days.

DRUG

Trastuzumab

Loading 2 mg/kg by vein then Maintenance 1 mg/kg by vein on Day 1

DRUG

Lapatinib

250 mg By Mouth Daily for 21 Days.

DRUG

Sunitinib

12.5 mg orally daily for 4 weeks, then 2 weeks off.

DRUG

Cetuximab

Loading 100 mg/m² by vein and Maintenance 75 mg/m² by vein on Days 1, 8, 15, 22

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00543504 - Bevacizumab in Multiple Phase I Combinations | Biotech Hunter | Biotech Hunter